10/552983

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Ignatius Loy BRITTO et al.

Serial No.: To be assigned
Filing Date: Currently herewith

Art Unit: To be assigned Examiner: To be assigned

For: A Medicament Dispenser.

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

		•
	ίi	Copies of the references listed on the attached form PTO-1449 as item nos. 2-3 and 7 are enclosed. Copies of the references were submitted in parent application Serial No
A.	[×]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR	
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

JC05 Rec'd PCT/PTO 12 OCT 2005

Atty. Docket No. PB60225USW

10/552983

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.						
In accordance with the requirements of 37 CFR 1.97(d):								
		Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]						
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and						
	[]	The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.						
[X]	-	charge any required fees to Deposit Account No.07-1392. icate copy of this paper is attached.						

Respectfully Submitted,

Robert J. Smith
Attorney of Record

Registration No. 40,820

Date: October 12, 2005

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-9616 Facsimile: (919) 483-7988

FORM PTO	1440			SERIAL NO. To be assigned							
		DISCLOSURE ST	ATEMENT		FILING DATE		Currently herewith				
INTORNA	11011	DISCLOSURE 51	ATEMENT		APPLICANT		Ignatius	Ignatius Loy BRITTO et			
					l'il Elemin	10	1755	2087			
					GROUP		To be ass	To be assigned			
					EXAMINER		To be assigned				
					ATTORNEY DOCKET NO. PB60225 USw						
U.S. PATENT DOCUMENTS											
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate			
	1.	6,007,954	12/28/1999	BORSEN	BERGER						
							-				
			C	ontinue on p	oage						
			FOREIG	N PATENT	DOCUMENTS	<u> </u>	·				
		Document	Publication					Translation			
	<u> </u>	Number	Date		Country	Class	Subclass	Yes No			
	2. ,	CA 2130867	02/28/1995	CA	<u> </u>			× .			
	3	GB 2,328,932A	03/10/1999	GB	=			×			
	4.	WO 99/42154	08/26/1999	PCT							
	5	WO 99/47195	09/23/1999	PCT							
	6.	WO 02/051483	07/04/2002	PCT		1					
	7	EP 1066073	12/06/2002	EPO				×			
	8. ·	WO 03/006181	01/23/2003	PCT		ļļ.					
	<u> </u>	ļ <u></u>				-					
	ļ				<u> </u>	 					
_	<u></u>		L	<u> </u>		<u> </u>		L			
				ontinue on p							
		OTHER DOCUM	1ENTS (Includi	ng Author,	Title, Journal-Da	ate, Page Numb	er, Etc.)				
								·			
							<u>-</u>				
	 -										
	+		-								
				 .							
	+			_							
	_				·	· · · · · · · · · · · · · · · · · · ·					
		· · · · · · · · · · · · · · · · · · ·									
<u>l_</u>			-	Continue on	nage		-				
EXAMINER DATE CONSIDERED											
272 114111 1211	•										
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through											

